The board of directors of Sun Pharmaceutical Industries Limited at their meeting held on May 26, 2023, inter alia, have approved the following: appointment of Mr. Rolf Hoffmann as an Independent Director. Mr. Rolf Hoffmann has been appointed as Independent Director for a term of five years to be effective from the date of allotment of Director Identification Number. Appointment of Mr. Aalok Shanghvi as a Whole-time Director.

Mr. Aalok Shanghvi has been appointed as a Whole-time Director, for a term of five years effective from June 1, 2023. Mr. Rolf Hoffmann is a Strategic and results-orientated Executive who is highly respected for expertise in creating and optimizing commercial opportunities in all global markets. He has over 29 years of experience managing top 50 worldwide markets with full P&L and cross-functional accountability.

Mr. Hoffmann has worked with Eli Lilly and Company for over a 17-year period with a balance of in-country management, international regional management and headquarters global executive positions. In his various responsibilities, he established a regulatory and governmental affairs network around the world, developed in-depth commercial capabilities for all geographies including alliances, joint venture, and organic growth strategy. Mr. Hoffmann was a highly respected operational leader and presenter with continued upward momentum when recruited by Amgen, where he spent about 12-years at various leadership roles and responsibilities, including P&L accountabilities for all countries around the world including the USA.

Mr. Hoffmann has served on various board viz., Ferring Holding Inc., New Jersey, USA, Trizell Holding S.A., Lausanne, Switzerland, Shield Therapeutics PLC, Gateshead Quays, UK, EUSA Pharma, Hemel Hempstead, UK, Biotest AG, Dreieich, Germany, Trigemina Inc., San Francisco, USA and STADA AG, Bad Vilbel, Germany. He currently serves the board of Genmab A/S, Copenhagen, Denmark, Paratek Pharmaceuticals Inc., Boston, USA, Semdor Pharma Group GmbH, Cologne, Germany and IDT Biologika GmbH, Dessau-Rosslau, Germany. Mr. Hoffmann has received an MBA, Kenan-Flagler Business School, UNC Chapel Hill, North Carolina, 1987, MA - English, The University of Koeln, Koeln, Germany, 1985 and MA - Kinesiology, Deutsche Sporthochschule Koeln, Koeln, Germany, 1985.

Mr. Aalok Shanghvi, Executive Vice-President, Head - Emerging Markets, Global Generic R&D, Global Generic Business Development & API. Aalok joined Sun in 2006 and has handled various roles in Marketing, R&D, Project Management, Purchase & Communications. In 2010, he headed Bangladesh and by 2014, he took over the Emerging Markets business, which is spread across 80 countries covering Africa, Middle East, APAC, Eastern Europe, CIS, and Latam.

Subsequently, he also took charge of Global Generic R&D, Global Generic Business Development and API. He has done his undergraduate majoring in Cellular and Molecular Biology from the University of Michigan - Ann Arbor.